

Fibroblast Growth Factor 19 (FGF-19) (Human)

**ELISA KIT PROTOCOL
(Catalog No.: EK-073-41)**



PHOENIX PHARMACEUTICALS, INC.

TABLE OF CONTENT

Introduction	3
Protocol Overview	4
List of Components	6
Materials Required but Not Supplied	6
Reagent Preparation	7
Human Fibroblast Growth Factor 19 (FGF-19)	8
Standard Preparation	
Human Fibroblast Growth Factor 19 (FGF-19)	9
ELISA Protocol	
Additional Recommended Procedural Note	11
Summary of Assay Protocol	12
Calculation of Results	13
Storage	14
Note	14
References	14

CAUTION:

Investigational device. Limited by law to investigational use. For research use only. Not for use in diagnostic procedures.

INTRODUCTION

FGF's are expressed during embryonic development and in restricted adult tissues. They are most commonly found on mesodermal and neuroectodermal cells and are involved in the regulation of diverse physiological functions. These functions include: angiogenesis, cell growth, embryonic development, metabolic regulation, cell migration, and tissue repair.

PROTOCOL OVERVIEW


The immunoplate in this kit is precoated with anti-Human Fibroblast Growth Factor 19 (FGF-19) Capture Antibody and the nonspecific binding sites are blocked. The Human Fibroblast Growth Factor 19 (FGF-19) in the sample or in the standard solution can bind to the capture antibody immobilized in the wells. After washing procedure, the anti-Human Fibroblast Growth Factor 19 (FGF-19) Detection Antibody which can bind to the Human Fibroblast Growth Factor 19 (FGF-19) trapped in the wells is added. After washing, the Horseradish Peroxidase (HRP) which catalyzes the Substrate Solution (TMB) is added. The enzyme-substrate reaction is terminated by the addition of a stop solution. The intensity of the color is directly proportional to the amount of Human Fibroblast Growth Factor 19 (FGF-19) in the standard solutions or samples. A standard curve of Human Fibroblast Growth Factor 19 (FGF-19) with known concentration can be established accordingly. The Human Fibroblast Growth Factor 19 (FGF-19) with unknown concentration in samples can be determined by extrapolation to this standard curve.

ASSAY CONDITIONS

Plasma, serum, culture media, tissue homogenate, CSF, urine or any biological fluid can be assayed as long as the level of the sample is high enough the for the sensitivity of the kit to detect it.

Phoenix Pharmaceuticals guarantees that its products conform to the information contained in this publication. The purchaser must determine the suitability of the product for its particular use and establish optimum sample concentrations.

ASSAY PRINCIPLE



LIST OF COMPONENTS

Store all components at 4°C. DO NOT FREEZE.

1. 20x Assay Buffer Concentrate (*50ml*).....**Catalog No. EK-BUF**
2. 96 Well anti-Human Fibroblast.....**Catalog No. EK-Plate-073-41**
Growth Factor 19 (FGF-19) Capture Antibody-Coated Plate (*1 plate*)
3. Human Fibroblast Growth.....**Catalog No. EK-S-073-41**
Factor 19 (FGF-19) Standard(*2,000pg/vial*)
4. Biotinylated anti-Human Fibroblast.....**Catalog No. EK-D-073-41**
Growth Factor 19 (FGF-19) Detection Antibody (*1 vial*)
5. Human Fibroblast Growth.....**Catalog No. EK-PC-073-41**
Growth Factor 19 (FGF-19) Positive Control (*2 vials*)
6. Streptavidin-Horseradish Peroxidase.....**Catalog No. EK-SA-HRP**
(HRP) (*30μl*)
7. Substrate Solution (TMB) (*12ml*).....**Catalog No. EK-SS**
8. Stop Solution 2N HCl (*15ml*)**Catalog No. EK-HCL**
9. Acetate Plate Sealer (APS) (*3 pieces*).....**Catalog No. EK-APS**
10. Assay Diagram (*1 sheet*)

MATERIALS REQUIRED BUT NOT SUPPLIED

- Micropipettor(s) and disposable pipette tips
- Multi-channel pipette capable of dispensing 50-100μl
- Solution Reservoir (*recommended*)
- Microtiter plate washer (*recommended*)
- Orbital plate shaker capable of 300-500 rpm (*recommended*)
- Microtiter plate reader capable of absorbance measurement 450nm
- Well-closed containers (15ml tubes or more in capacity)
- Absorbent material for blotting

REAGENT PREPARATION

Note: *The kit should be equilibrated to room temperature (20-23°C) before opening any vials and starting the assay. It is highly recommended that the solutions be used as soon as possible after rehydration.*

1. **1x Assay Buffer:** Dilute the **20x Assay Buffer Concentrate** with 950ml of distilled water. This assay buffer will be used to wash the plate and reconstitute all of the other components in this kit. If crystals are observed in the **20x Assay Buffer** warm the bottle in a 37°C water bath for approximately 30 minutes or until the crystals disappear. After preparation, store **1x Assay Buffer** at 4°C.
2. **Anti-Human Fibroblast Growth Factor 19 (FGF-19) Detection Antibody:** Rehydrate anti-Human Fibroblast Growth Factor 19 (FGF-19) Detection Antibody with 100µl of **1x assay buffer**, vortex (centrifuge the tube to dislodge powder from the cap or walls). Dilute anti-Human Fibroblast Growth Factor 19 (FGF-19) Detection Antibody to 1:100 and mix thoroughly before use.
3. **Streptavidin-Horseradish Peroxidase (SA-HRP):** Centrifuge the SA-HRP vial (30µl) provided in this kit (3,000-5,000 rpm, 5 seconds) and dilute HRP with **1x assay buffer** to 1:2000 before use. Vortex thoroughly.
4. **Human Fibroblast Growth Factor 19 (FGF-19) Positive Control:** Rehydrate Human Fibroblast Growth Factor 19 (FGF-19) Positive Control with 250µl of **1x assay buffer** (centrifuge the tube to dislodge powder from cap or walls). Vortex thoroughly.


HUMAN FGF-19 STANDARD PREPARATION

1. Rehydrate recombinant Human Growth Factor 19 (FGF-19) Standard with 1ml **1x Assay Buffer**, vortex. Allow the solution to sit at least 10 minutes at room temperature (20-23°C) to completely dissolve in solution. Vortex and centrifuge before use. The concentration of this stock solution is 2,000pg/ml.

2. Prepare Standard solutions as follows:

Standard No.	Standard Protein Volume	Assay Buffer Volume	Concentration
Stock	Powder	1000µl	2,000pg/ml
#1	300µl of Stock	300µl	1000pg/ml
#2	300µl of #1	300µl	500pg/ml
#3	300µl of #2	300µl	250pg/ml
#4	300µl of #3	300µl	125pg/ml
#5	300µl of #4	300µl	62.5pg/ml
#6	300µl of #5	300µl	31.2pg/ml
#7	300µl of #6	300µl	15.6pg/ml

Table of Standard Dilutions



Immunoplate loading map

Visual Guide of the Standard Dilutions

HUMAN FGF-19 ELISA PROTOCOL

1. Thoroughly read this protocol before performing an assay. Allow all reagents to come to room temperature (20-23°C) prior to the start of the assay.
2. Remove Capture Antibody-Coated Plate from its zip-lock foil pouch. Remove unneeded strips from the plate frame, reseal them in the foil pouch, and return the foil pouch to 4°C.
3. Wash each well with 350µl of **1x Assay Buffer**. Allow it to sit for at least five minutes. Discard the buffer, invert and blot dry plate. Do not let wells dry before proceeding to the next step.
4. Leave wells A-1 and A-2 empty as **Blank**.
5. Add 100µl of the prepared Human FGF-19 Standard solutions from #7 to #1 (reverse order of serial dilution) in duplicate to each well.
6. Add 100µl of Human FGF-19 Positive Control solution in duplicate.
7. Add 100µl diluted samples in duplicate into their designated wells.
8. Seal the immunoplate with Acetate Plate Sealer (APS). Incubate for 2 hours at room temperature (20-23°C) on a plate shaker (300-400 rpm).
9. Before washing the plate, remove the plate sealer carefully. Completely discard the liquid from wells. Wash each well with 300-350µl assay buffer four times. At the end of each wash, discard the buffer, invert the plate, and tap on a clean absorbent towel.
10. Add 100µl anti-Human FGF-19 Detection Antibody into each well. Reseal the immunoplate with plate sealer and incubate for 2 hours at room temperature (20-23°C) on a plate shaker (300-400rpm).
11. Wash 4 times with the **1x Assay Buffer** as described in step 9.
12. Add 100µl SA-HRP solution into each well. Reseal the immunoplate with plate sealer and incubate the plate for 30 minutes at room temperature (20-23°C) on plate shaker (300-400rpm).

13. Wash 4 times with the **1x** Assay Buffer as described in step 9.
14. Add 100 μ l Substrate Solution (TMB) provided in this kit into each well. Reseal the plate with plate sealer to protect from light and incubate the plate for 20-30 minutes at room temperature (20-23°C) on a plate shaker (300-400 rpm).
15. Add 100 μ l Stop Solution (2N Hydrochloric Acid) into each well to stop the reaction. The color in the well should change from blue to yellow. If the color change does not appear to be uniform, gently tap the plate to ensure thorough mixing. Proceed to the next step within 20 minutes.
16. Read Absorbance O.D. at 450nm using a Microtiter Plate Reader.

ADDITIONAL RECOMMENDED PROCEDURAL NOTES:

- Reagents of different lot numbers should not be mixed.
- Recheck the reagent labels when loading the plate to ensure that everything is added correctly.
- Unused microplate strips should be placed in the foil pouch with a desiccant and stored at 4°C. Do not allow moisture to enter the wells.
- When handling the plate, avoid touching the bottom.
- Manual washing may cause high duplicate coefficient variations. To reduce this factor, liquid from the plate should be removed by inverting and blotting the plate on an absorbent material.
- If the room temperature is not within the suggested range (20-23°C), variations in results may occur.
- The same reservoir for the reagents may be reused if the reservoir is washed well with distilled water before each use.
- Each laboratory must determine the appropriate dilution factors for the samples to be measured to ensure that the samples are within the dynamic range of the standard curve.
- High levels of interfering proteins may cause variations within the sample results. Therefore, it is imperative to select the appropriate sample preparation procedure to obtain the optimal results.
- Each time a new tip is used, make sure the tip is secure and free of air bubbles. For better intra-assay variation, aspirate and expel a reagent or sample back into the container a few times prior to loading.
- Avoid submerging the whole tip into reagents because droplets can accumulate at the end of the tip causing an excess of reagent to be loaded into the well. This can lead to poor results.
- For optimal results, an orbital plate shaker capable of 300-500 rpm is recommended for all incubations.
- Modification of the existing protocol (i.e. standard dilutions, pipetting technique, washing technique, incubation time or temperature, storage conditions, and kit expiration) may affect the sensitivity and specificity of the test.

SUMMARY OF ASSAY PROTOCOL


- Add 100 μ l/well of FGF-19 standard, sample, or positive control
except the Blank wells
- Incubate at room temperature (20-23°C) for 2 hours
- Wash immunoplate 4 times with 350 μ l/well of 1x assay buffer
- Add 100 μ l/well of anti-FGF-19
Detection Antibody
- Incubate at room temperature (20-23°C) for 2 hours
- Wash immunoplate 4 times with 350 μ l/well of **1x** assay buffer
- Add 100 μ l/well of SA-HRP solution
- Incubate at room temperature (20-23°C) for 30 minutes
- Wash immunoplate 4 times with 350 μ l/well of **1x** assay buffer
- Add 100 μ l/well of Substrate Solution (TMB)
- Incubate at room temperature (20-23°C) for 20-30 minutes
- Terminate reaction with 100 μ l/well of 2N HCL
- Read absorbance O.D. at **450nm** and calculate results

CALCULATION OF RESULTS

Plot the standard curve on log-log graph paper. Known concentration of Human FGF-19 Standard and its corresponding O.D. reading is plotted on the log scale (X-axis) and the log scale (Y-axis), respectively. The standard curve shows a correlated relationship between Human FGF-19 concentrations and the corresponding O.D. absorbance. As the standard concentration increases, the intensity of the yellow color, and in turn the O.D. absorbance, increases.

The concentration of Human FGF-19 within a sample is determined by plotting the sample's O.D. on the Y-axis, then drawing a horizontal line to intersect with the standard curve. A vertical line dropped from this point will intersect the X-axis at a coordinate corresponding to the Human FGF-19 concentration in the unknown sample.

Refer to QC Data sheet for acceptable values of the positive control.



STORAGE

1. Store the kit at 4°C upon receipt. The kit should be equilibrated to room temperature (20-23°C) before assay.
2. Store **1x Assay Buffer** at 4°C.
3. Remove any unneeded strips from Human FGF-19 antibody-Coated plate, reseal them in zip-lock foil and keep at 4°C.
4. Keep rehydrated solution of Human FGF-19 Standard, anti-Human FGF-19 Detection Antibody and SA-HRP at 4°C. Prepare only the required amount.

NOTE:

1. It is recommended that the solutions be used on the same day of rehydration.
3. After adding Stop Solution, read the plate within 20 minutes.

REFERENCES

1. Nishimura, T. et al. (1999) Biochem. Biophys. Acta 1444:148.
2. Kharitonenkov A., Shyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozniak JT, Jawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;Jun: 115(6):1627-35.
3. Nicholas K. Gulliet S, Tomlinson E, Hillan K, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan JP, Stinson J, Stewart T, French DM. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 2002 Jun;160(6):2295-307.

